Urgent.News

600+ sources. One page. See who else covered it.

Editions

Health & Medicine

MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta

⏸️ MapLight Therapeutics pauses preclinical and discovery work: The biotech said it will instead focus its resources on advancing its lead candidate, ML-007C-MA, for schizophrenia and Alzheimer’s disease psychosis. MapLight also ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Friday 14 August →